Tissue Core

项目摘要 组织核心 组织核心（TC）是Moffitt癌症中心（Moffitt）的中央生物储存库。1992年开业， TC的总体目标是收集、处理、储存和发布高质量、注释良好的生物标本， 支持基础、临床、人口、定量和转化研究。TC提供各种各样的 服务包括新鲜冷冻组织采集、组织学、免疫组织化学、核酸提取、 组织微阵列的生成和存档生物样本的释放。此外，技术合作委员会还就 项目特定SOP，包括研究设计和采集策略，以优化标本处理。TC报价 75种不同的服务，达到或超过NCI最佳实践建议和CAP生物储存库 认证标准，确保样本采集和处理的严格性和可重复性， 通过标准化、文件化和质量管理进行验证。为实现其目标开展的技术合作活动包括 分为三个具体目标： 目标1：作为集中的Moffitt生物库资源，用于收集、处理和储存 生物标本 目标2：通过以下方式促进和确保获得高质量生物标本和最新科学服务 实施生物储藏最佳做法。 目标3：通过简化利用、生物标本教育和培训， 确保高质量的结果。 在上一个供资周期，技术合作服务继续提高效率、沟通和周转率 随着时间的推移，TC解决了标本采集的复杂性，以支持新的项目。这 产生了三个新的服务部门：生物标本处理服务，TC全面癌症护理科，以支持 Moffitt的机构资助的生物库方案，以及TC临床试验生物样本服务， 为临床试验提供专门支持。此外，TC还作为NIH联盟项目的活跃网站进行合作， 作为临床蛋白质组肿瘤分析联盟，提供生物标本收集，处理， 通过Moffitt的Total Cancer Care机构生物库方案进行传播和数据注释。TC也 作为NHLBI国家骨髓增生异常综合征自然史的中心实验室和生物储存库 Study.在过去五年中，技术合作为188份出版物（37份影响力大）和154份赠款做出了贡献。在20财年 仅TC就在所有五个计划中支持了120个成员（69%的同行评审得到资助）（CBE 18%，CE 18%，MM 31 %，HOB 5%，IO 28%）。TC在2020财年总共支持了350个协议。在这些协议中，有219项是 临床试验，从2019财年的93项增加到2018财年的64项。

PROJECT SUMMARY TISSUE CORE The Tissue Core (TC) serves as the central biorepository for Moffitt Cancer Center (Moffitt). Opened in 1992, the overall goal of TC is to collect, process, store, and release high-quality, well-annotated biospecimens in support of basic, clinical, population, quantitative and translational research. TC provides a wide variety of services including fresh frozen tissue collection, histology, immunohistochemistry, nucleic acid extraction, generation of tissue microarrays, and archived biospecimen release. Further, TC consults on and implements project-specific SOPs, including study design and collection strategies to optimize specimen handling. TC offers 75 distinct services that meet or exceed NCI best practice recommendations and CAP Biorepository Accreditation standards, which ensures rigor and reproducibility in sample collection and processing that is validated through standardization, documentation, and quality management. TC activities towards its goals are organized into three Specific Aims: Aim 1: To serve as the centralized Moffitt biobanking resource for the collection, processing, and storage of biospecimens. Aim 2: To facilitate and ensure access to high-quality biospecimens and state-of-the-science services through implementation of biorepository best practices. Aim 3: To enrich Member research through streamlined utilization, biospecimen education and training that ensures high-quality outcomes. Over the previous funding cycle, TC services continued to improve efficiency, communication, and turn-around times and the TC addressed the evolving complexity of specimen collection to support novel projects. This yielded three new service sections: Biospecimen Processing Services, TC Total Cancer Care Section to support Moffitt’s institutionally funded biobanking protocol, and TC Clinical Trial Biospecimen Services, which provides dedicated support for clinical trials. Further, TC collaborates as an active site for NIH consortium projects such as the Clinical Proteomic Tumor Analysis Consortium that provides biospecimen collection, processing, dissemination and data annotation via Moffitt’s Total Cancer Care institutional biobanking protocol. TC also serves as the Central Lab and Biorepository for NHLBI’s National Myelodysplastic Syndrome Natural History Study. Over the last five years, TC contributed to 188 publications (37 high impact) and 154 grants. In FY20 alone, TC supported 120 Members (69% peer review funded) in all five Programs (CBE 18 %, CE 18 %, MM 31 %, HOB 5%, IO 28%). Collectively, TC supported 350 protocols during FY20. Of those protocols, 219 were clinical trials, increasing from 93 in FY2019 and 64 in FY2018.